Trial Outcomes & Findings for Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) (NCT NCT04518995)

NCT ID: NCT04518995

Last Updated: 2023-05-03

Results Overview

SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

706 participants

Primary outcome timeframe

Week 24

Results posted on

2023-05-03

Participant Flow

Participants were enrolled at study centers in Canada, France, Poland, Spain and the United States from 23 November 2020 to 19 April 2022.

946 participants were screened, out of which 706 participants who experienced moderate to severe hair loss due to alopecia areata were enrolled to receive CTP-543 or placebo.

Participant milestones

Participant milestones
Measure
Placebo
Participants received CTP-543 matched placebo tablets, orally, twice daily (BID) for up to 24 weeks.
CTP-543 8 mg BID
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
CTP-543 12 mg BID
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Overall Study
STARTED
140
351
215
Overall Study
Efficacy Population
140
351
215
Overall Study
Safety Population
140
350
215
Overall Study
COMPLETED
129
318
199
Overall Study
NOT COMPLETED
11
33
16

Reasons for withdrawal

Reasons for withdrawal
Measure
Placebo
Participants received CTP-543 matched placebo tablets, orally, twice daily (BID) for up to 24 weeks.
CTP-543 8 mg BID
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
CTP-543 12 mg BID
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Overall Study
Treatment Emergent or Worsening Adverse Event
2
8
4
Overall Study
Lack of Efficacy
2
1
0
Overall Study
Non-compliance With Study Drug
0
3
2
Overall Study
Pregnancy
0
0
1
Overall Study
Protocol Violation
2
0
1
Overall Study
Reason not Specified
4
11
2
Overall Study
Lost to Follow-up
1
10
6

Baseline Characteristics

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Placebo
n=140 Participants
Participants received CTP-543 matched placebo tablets, orally, BID for up to 24 weeks.
CTP-543 8 mg BID
n=351 Participants
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
CTP-543 12 mg BID
n=215 Participants
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Total
n=706 Participants
Total of all reporting groups
Age, Continuous
38.7 years
STANDARD_DEVIATION 13.81 • n=99 Participants
38.9 years
STANDARD_DEVIATION 13.32 • n=107 Participants
38.2 years
STANDARD_DEVIATION 12.80 • n=206 Participants
38.6 years
STANDARD_DEVIATION 13.25 • n=7 Participants
Sex: Female, Male
Female
89 Participants
n=99 Participants
217 Participants
n=107 Participants
131 Participants
n=206 Participants
437 Participants
n=7 Participants
Sex: Female, Male
Male
51 Participants
n=99 Participants
134 Participants
n=107 Participants
84 Participants
n=206 Participants
269 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
11 Participants
n=99 Participants
30 Participants
n=107 Participants
13 Participants
n=206 Participants
54 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
119 Participants
n=99 Participants
292 Participants
n=107 Participants
188 Participants
n=206 Participants
599 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
10 Participants
n=99 Participants
29 Participants
n=107 Participants
14 Participants
n=206 Participants
53 Participants
n=7 Participants
Race/Ethnicity, Customized
Race · American Indian or Alaska Native
0 Participants
n=99 Participants
2 Participants
n=107 Participants
1 Participants
n=206 Participants
3 Participants
n=7 Participants
Race/Ethnicity, Customized
Race · Asian
10 Participants
n=99 Participants
22 Participants
n=107 Participants
21 Participants
n=206 Participants
53 Participants
n=7 Participants
Race/Ethnicity, Customized
Race · Black or African American
16 Participants
n=99 Participants
40 Participants
n=107 Participants
27 Participants
n=206 Participants
83 Participants
n=7 Participants
Race/Ethnicity, Customized
Race · Native Hawaiian or other Pacific Islander
1 Participants
n=99 Participants
3 Participants
n=107 Participants
1 Participants
n=206 Participants
5 Participants
n=7 Participants
Race/Ethnicity, Customized
Race · White
98 Participants
n=99 Participants
241 Participants
n=107 Participants
145 Participants
n=206 Participants
484 Participants
n=7 Participants
Race/Ethnicity, Customized
Race · Other
5 Participants
n=99 Participants
17 Participants
n=107 Participants
6 Participants
n=206 Participants
28 Participants
n=7 Participants
Race/Ethnicity, Customized
Race · Not reported
10 Participants
n=99 Participants
26 Participants
n=107 Participants
14 Participants
n=206 Participants
50 Participants
n=7 Participants

PRIMARY outcome

Timeframe: Week 24

Population: Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period.

SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).

Outcome measures

Outcome measures
Measure
Placebo
n=140 Participants
Participants received CTP-543 matched placebo tablets, orally, BID for up to 24 weeks.
CTP-543 8 mg BID
n=351 Participants
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
CTP-543 12 mg BID
n=215 Participants
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score of ≤20 at Week 24
0.8 percentage of participants
29.6 percentage of participants
41.5 percentage of participants

SECONDARY outcome

Timeframe: Weeks 12, 16, 20, and 24

Population: Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period.

SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied. Responders were defined as participants with responses of "satisfied" or "very satisfied".

Outcome measures

Outcome measures
Measure
Placebo
n=140 Participants
Participants received CTP-543 matched placebo tablets, orally, BID for up to 24 weeks.
CTP-543 8 mg BID
n=351 Participants
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
CTP-543 12 mg BID
n=215 Participants
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Percentage of Responders on the Hair Satisfaction Patient Reported Outcome (SPRO) Scale at Weeks 12, 16, 20, and 24
Week 12
11.9 percentage of responders
35.3 percentage of responders
46.4 percentage of responders
Percentage of Responders on the Hair Satisfaction Patient Reported Outcome (SPRO) Scale at Weeks 12, 16, 20, and 24
Week 16
8.3 percentage of responders
38.2 percentage of responders
51.5 percentage of responders
Percentage of Responders on the Hair Satisfaction Patient Reported Outcome (SPRO) Scale at Weeks 12, 16, 20, and 24
Week 20
6.1 percentage of responders
37.4 percentage of responders
54.0 percentage of responders
Percentage of Responders on the Hair Satisfaction Patient Reported Outcome (SPRO) Scale at Weeks 12, 16, 20, and 24
Week 24
4.7 percentage of responders
42.1 percentage of responders
53.0 percentage of responders

SECONDARY outcome

Timeframe: Weeks 4, 8, 12, 16, and 20

Population: Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period.

SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).

Outcome measures

Outcome measures
Measure
Placebo
n=140 Participants
Participants received CTP-543 matched placebo tablets, orally, BID for up to 24 weeks.
CTP-543 8 mg BID
n=351 Participants
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
CTP-543 12 mg BID
n=215 Participants
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Percentage of Participants Achieving an Absolute SALT Score of ≤20 at Weeks 4, 8, 12, 16, and 20
Week 4
0 percentage of participants
0.9 percentage of participants
0 percentage of participants
Percentage of Participants Achieving an Absolute SALT Score of ≤20 at Weeks 4, 8, 12, 16, and 20
Week 8
0 percentage of participants
3.3 percentage of participants
6.1 percentage of participants
Percentage of Participants Achieving an Absolute SALT Score of ≤20 at Weeks 4, 8, 12, 16, and 20
Week 12
0.7 percentage of participants
10.4 percentage of participants
18.2 percentage of participants
Percentage of Participants Achieving an Absolute SALT Score of ≤20 at Weeks 4, 8, 12, 16, and 20
Week 16
2.3 percentage of participants
16.5 percentage of participants
29.6 percentage of participants
Percentage of Participants Achieving an Absolute SALT Score of ≤20 at Weeks 4, 8, 12, 16, and 20
Week 20
0.8 percentage of participants
24.1 percentage of participants
37.0 percentage of participants

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, and 24

Population: Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. Overall number of participants analyzed indicates the number of participants with data available for analysis of this outcome measure. Number of participants analyzed indicates the number of participants with data available for analysis at the specified timepoint.

SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[post-baseline SALT score - baseline SALT score\]/baseline SALT score).

Outcome measures

Outcome measures
Measure
Placebo
n=139 Participants
Participants received CTP-543 matched placebo tablets, orally, BID for up to 24 weeks.
CTP-543 8 mg BID
n=345 Participants
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
CTP-543 12 mg BID
n=212 Participants
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Relative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24
Relative Change From Baseline at Week 4
-0.2 percent change
Standard Deviation 5.59
-2.6 percent change
Standard Deviation 12.79
-4.0 percent change
Standard Deviation 12.03
Relative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24
Relative Change From Baseline at Week 8
-2.3 percent change
Standard Deviation 11.41
-10.9 percent change
Standard Deviation 21.00
17.5 percent change
Standard Deviation 27.16
Relative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24
Relative Change From Baseline at Week 12
-0.6 percent change
Standard Deviation 16.63
-22.2 percent change
Standard Deviation 29.45
-31.1 percent change
Standard Deviation 35.53
Relative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24
Relative Change From Baseline at Week 16
-1.8 percent change
Standard Deviation 21.06
-30.3 percent change
Standard Deviation 34.20
-41.2 percent change
Standard Deviation 38.95
Relative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24
Relative Change From Baseline at Week 20
-1.3 percent change
Standard Deviation 22.14
-36.0 percent change
Standard Deviation 37.82
-46.8 percent change
Standard Deviation 41.32
Relative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24
Relative Change From Baseline at Week 24
-1.5 percent change
Standard Deviation 23.30
-41.2 percent change
Standard Deviation 39.37
-50.4 percent change
Standard Deviation 41.52

SECONDARY outcome

Timeframe: Weeks 12, 16, 20, and 24

Population: Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period.

The CGI-I is a questionnaire that asks the clinician to evaluate the improvement or worsening of the participant's alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved).

Outcome measures

Outcome measures
Measure
Placebo
n=140 Participants
Participants received CTP-543 matched placebo tablets, orally, BID for up to 24 weeks.
CTP-543 8 mg BID
n=351 Participants
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
CTP-543 12 mg BID
n=215 Participants
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Percentage of Responders Assessed Using the Clinician Global Impression of Improvement (CGI-I) at Weeks 12, 16, 20, and 24
Week 12
3.7 percentage of responders
36.3 percentage of responders
43.5 percentage of responders
Percentage of Responders Assessed Using the Clinician Global Impression of Improvement (CGI-I) at Weeks 12, 16, 20, and 24
Week 16
7.7 percentage of responders
44.2 percentage of responders
54.7 percentage of responders
Percentage of Responders Assessed Using the Clinician Global Impression of Improvement (CGI-I) at Weeks 12, 16, 20, and 24
Week 20
8.4 percentage of responders
49.1 percentage of responders
57.1 percentage of responders
Percentage of Responders Assessed Using the Clinician Global Impression of Improvement (CGI-I) at Weeks 12, 16, 20, and 24
Week 24
9.4 percentage of responders
53.8 percentage of responders
59.8 percentage of responders

SECONDARY outcome

Timeframe: Weeks 12, 16, 20, and 24

Population: Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period.

The PGI-I is a self-administered questionnaire that asks the participant to evaluate the improvement or worsening of their alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved).

Outcome measures

Outcome measures
Measure
Placebo
n=140 Participants
Participants received CTP-543 matched placebo tablets, orally, BID for up to 24 weeks.
CTP-543 8 mg BID
n=351 Participants
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
CTP-543 12 mg BID
n=215 Participants
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Percentage of Responders Assessed Using the Patient Global Impression of Improvement (PGI-I) at Weeks 12, 16, 20, and 24
Week 12
6.7 percentage of responders
38.9 percentage of responders
49.8 percentage of responders
Percentage of Responders Assessed Using the Patient Global Impression of Improvement (PGI-I) at Weeks 12, 16, 20, and 24
Week 16
9.0 percentage of responders
49.1 percentage of responders
58.3 percentage of responders
Percentage of Responders Assessed Using the Patient Global Impression of Improvement (PGI-I) at Weeks 12, 16, 20, and 24
Week 20
10.0 percentage of responders
50.6 percentage of responders
60.0 percentage of responders
Percentage of Responders Assessed Using the Patient Global Impression of Improvement (PGI-I) at Weeks 12, 16, 20, and 24
Week 24
10.2 percentage of responders
56.6 percentage of responders
65.5 percentage of responders

SECONDARY outcome

Timeframe: Baseline, Weeks 12, 16, 20, and 24

Population: Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. Overall number of participants analyzed indicates the number of participants with data available for analysis of this outcome measure. Number of participants analyzed indicates the number of participants with data available for analysis at the specified timepoint.

The CGI-S is a questionnaire that asks the clinician to evaluate the symptom severity of the participant's alopecia areata at the time of assessment. The symptom severity was rated on a scale ranging from 1 to 7, where 1=normal, no hair loss; 2=borderline hair loss; 3=mild hair loss; 4=moderate hair loss; 5=marked hair loss; 6=severe hair loss; 7=among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.

Outcome measures

Outcome measures
Measure
Placebo
n=136 Participants
Participants received CTP-543 matched placebo tablets, orally, BID for up to 24 weeks.
CTP-543 8 mg BID
n=328 Participants
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
CTP-543 12 mg BID
n=209 Participants
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Change in the Clinician Global Impression of Severity (CGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24
Baseline
6.5 score on a scale
Standard Deviation 0.74
6.4 score on a scale
Standard Deviation 0.86
6.4 score on a scale
Standard Deviation 0.76
Change in the Clinician Global Impression of Severity (CGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24
Change From Baseline at Week 12
-0.1 score on a scale
Standard Deviation 0.74
-1.0 score on a scale
Standard Deviation 1.38
-1.4 score on a scale
Standard Deviation 1.53
Change in the Clinician Global Impression of Severity (CGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24
Change From Baseline at Week 16
-0.2 score on a scale
Standard Deviation 0.99
-1.3 score on a scale
Standard Deviation 1.55
-1.9 score on a scale
Standard Deviation 1.77
Change in the Clinician Global Impression of Severity (CGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24
Change From Baseline at Week 20
-0.1 score on a scale
Standard Deviation 0.83
-1.6 score on a scale
Standard Deviation 1.77
-2.2 score on a scale
Standard Deviation 1.92
Change in the Clinician Global Impression of Severity (CGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24
Change From Baseline at Week 24
-0.2 score on a scale
Standard Deviation 0.90
-1.9 score on a scale
Standard Deviation 1.89
-2.4 score on a scale
Standard Deviation 2.03

SECONDARY outcome

Timeframe: Baseline, Weeks 12, 16, 20, and 24

Population: Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. Overall number of participants analyzed indicates the number of participants with data available for analysis of this outcome measure. Number of participants analyzed indicates the number of participants with data available for analysis at the specified timepoint.

The PGI-S is a self-administered questionnaire that asks the participant to evaluate the symptom severity of their alopecia areata at the time of assessment. Symptom severity was rated on a scale ranging from 1 to 7, where 1=normal, no hair loss; 2=borderline hair loss; 3=mild hair loss; 4=moderate hair loss; 5=marked hair loss; 6=severe hair loss; 7=among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.

Outcome measures

Outcome measures
Measure
Placebo
n=137 Participants
Participants received CTP-543 matched placebo tablets, orally, BID for up to 24 weeks.
CTP-543 8 mg BID
n=329 Participants
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
CTP-543 12 mg BID
n=209 Participants
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Change in the Patient Global Impression of Severity (PGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24
Baseline
6.5 score on a scale
Standard Deviation 0.76
6.5 score on a scale
Standard Deviation 0.80
6.4 score on a scale
Standard Deviation 0.86
Change in the Patient Global Impression of Severity (PGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24
Change From Baseline at Week 12
-0.4 score on a scale
Standard Deviation 1.08
-1.1 score on a scale
Standard Deviation 1.64
-1.4 score on a scale
Standard Deviation 1.79
Change in the Patient Global Impression of Severity (PGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24
Change From Baseline at Week 16
-0.2 score on a scale
Standard Deviation 0.78
-1.5 score on a scale
Standard Deviation 1.83
-2.0 score on a scale
Standard Deviation 1.95
Change in the Patient Global Impression of Severity (PGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24
Change From Baseline at Week 20
-0.3 score on a scale
Standard Deviation 1.01
-1.8 score on a scale
Standard Deviation 2.01
-2.2 score on a scale
Standard Deviation 2.07
Change in the Patient Global Impression of Severity (PGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24
Change From Baseline at Week 24
-0.1 score on a scale
Standard Deviation 0.74
-1.9 score on a scale
Standard Deviation 2.05
-2.4 score on a scale
Standard Deviation 2.14

SECONDARY outcome

Timeframe: Baseline, Weeks 12, and 24

Population: Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period.

SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Percentage of participants achieving at least a 75% and 90% relative reduction in SALT score from baseline at Weeks 12 and 24 are reported.

Outcome measures

Outcome measures
Measure
Placebo
n=140 Participants
Participants received CTP-543 matched placebo tablets, orally, BID for up to 24 weeks.
CTP-543 8 mg BID
n=351 Participants
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
CTP-543 12 mg BID
n=215 Participants
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Percentage of Participants Achieving at Least a 75% and 90% Relative Reduction in SALT Score From Baseline at Weeks 12 and 24
75% Relative Reduction: Week 12
0 percentage of participants
8.8 percentage of participants
17.7 percentage of participants
Percentage of Participants Achieving at Least a 75% and 90% Relative Reduction in SALT Score From Baseline at Weeks 12 and 24
75% Relative Reduction: Week 24
0 percentage of participants
28.6 percentage of participants
40.0 percentage of participants
Percentage of Participants Achieving at Least a 75% and 90% Relative Reduction in SALT Score From Baseline at Weeks 12 and 24
90% Relative Reduction: Week 12
0 percentage of participants
3.4 percentage of participants
10.0 percentage of participants
Percentage of Participants Achieving at Least a 75% and 90% Relative Reduction in SALT Score From Baseline at Weeks 12 and 24
90% Relative Reduction: Week 24
0 percentage of participants
19.2 percentage of participants
32.0 percentage of participants

SECONDARY outcome

Timeframe: Baseline, Weeks 12, and 24

Population: Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. Overall number of participants analyzed indicates the number of participants with data available for analysis of this outcome measure. Number of participants analyzed indicates the number of participants with data available for analysis at the specified timepoint.

BETA is a clinician-rated scale that assesses the total eyebrow hair present. The BETA score is calculated based on hair density and surface area of each individual eyebrow of the participant, ranging from 0 to 3, where 0 = no eyebrow, 1 = minimal eyebrow, 2 = moderate eyebrow, 3 = normal eyebrow. The BETA score is the sum of the right and left eyebrow scores, ranging from 0 to 6. Higher scores indicate less hair loss of eyebrows. A positive change from baseline indicates less hair loss of eyebrows.

Outcome measures

Outcome measures
Measure
Placebo
n=83 Participants
Participants received CTP-543 matched placebo tablets, orally, BID for up to 24 weeks.
CTP-543 8 mg BID
n=204 Participants
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
CTP-543 12 mg BID
n=132 Participants
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Change in the Brigham Eyebrow Tool for Alopecia (BETA) Scores From Baseline at Weeks 12 and 24
Baseline
1.7 score on a scale
Standard Deviation 2.05
1.2 score on a scale
Standard Deviation 1.77
1.4 score on a scale
Standard Deviation 1.91
Change in the Brigham Eyebrow Tool for Alopecia (BETA) Scores From Baseline at Weeks 12 and 24
Change From Baseline at Week 12
-0.2 score on a scale
Standard Deviation 1.38
0.8 score on a scale
Standard Deviation 1.70
1.1 score on a scale
Standard Deviation 2.05
Change in the Brigham Eyebrow Tool for Alopecia (BETA) Scores From Baseline at Weeks 12 and 24
Change From Baseline at Week 24
-0.2 score on a scale
Standard Deviation 1.68
1.6 score on a scale
Standard Deviation 1.96
1.8 score on a scale
Standard Deviation 2.17

SECONDARY outcome

Timeframe: Baseline, Weeks 12, and 24

Population: Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. Overall number of participants analyzed indicates the number of participants with data available for analysis of this outcome measure. Number of participants analyzed indicates the number of participants with data available for analysis at the specified timepoint.

BELA is a clinician-rated scale that assesses the total eyelash hair present. The BELA is calculated based on distribution and grade values, ranging from 0 (no eyelashes) to 3 (full eyelashes). The BELA score is the sum of the individual scores for the left and right eyes, ranging from 0 to 6. Higher scores indicate less hair loss of eyelashes. A positive change from baseline indicates less hair loss of eyelashes.

Outcome measures

Outcome measures
Measure
Placebo
n=86 Participants
Participants received CTP-543 matched placebo tablets, orally, BID for up to 24 weeks.
CTP-543 8 mg BID
n=219 Participants
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
CTP-543 12 mg BID
n=150 Participants
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Change in the Brigham Eyelash Tool for Alopecia (BELA) Scores From Baseline at Weeks 12 and 24
Baseline
1.5 score on a scale
Standard Deviation 2.12
1.4 score on a scale
Standard Deviation 2.10
1.7 score on a scale
Standard Deviation 2.12
Change in the Brigham Eyelash Tool for Alopecia (BELA) Scores From Baseline at Weeks 12 and 24
Change From Baseline at Week 12
-0.1 score on a scale
Standard Deviation 1.18
0.9 score on a scale
Standard Deviation 1.50
1.3 score on a scale
Standard Deviation 2.08
Change in the Brigham Eyelash Tool for Alopecia (BELA) Scores From Baseline at Weeks 12 and 24
Change From Baseline at Week 24
0.3 score on a scale
Standard Deviation 1.30
1.7 score on a scale
Standard Deviation 1.99
2.0 score on a scale
Standard Deviation 2.28

SECONDARY outcome

Timeframe: Baseline, Weeks 12, 16, 20, and 24

Population: Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. Overall number of participants analyzed indicates the number of participants with data available for analysis of this outcome measure. Number of participants analyzed indicates the number of participants with data available for analysis at the specified timepoint.

SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied. Higher scores indicate the greater hair dissatisfaction. A negative change from baseline indicate the greater hair satisfaction.

Outcome measures

Outcome measures
Measure
Placebo
n=137 Participants
Participants received CTP-543 matched placebo tablets, orally, BID for up to 24 weeks.
CTP-543 8 mg BID
n=329 Participants
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
CTP-543 12 mg BID
n=209 Participants
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Change in the SPRO Scale From Baseline at Weeks 12, 16, 20, and 24
Baseline
4.5 score on a scale
Standard Deviation 0.86
4.5 score on a scale
Standard Deviation 0.89
4.5 score on a scale
Standard Deviation 0.85
Change in the SPRO Scale From Baseline at Weeks 12, 16, 20, and 24
Change From Baseline at Week 12
-0.6 score on a scale
Standard Deviation 1.15
-1.3 score on a scale
Standard Deviation 1.42
-1.7 score on a scale
Standard Deviation 1.36
Change in the SPRO Scale From Baseline at Weeks 12, 16, 20, and 24
Change From Baseline at Week 16
-0.4 score on a scale
Standard Deviation 1.18
-1.4 score on a scale
Standard Deviation 1.44
-1.8 score on a scale
Standard Deviation 1.43
Change in the SPRO Scale From Baseline at Weeks 12, 16, 20, and 24
Change From Baseline at Week 20
-0.4 score on a scale
Standard Deviation 1.14
-1.4 score on a scale
Standard Deviation 1.52
-1.8 score on a scale
Standard Deviation 1.52
Change in the SPRO Scale From Baseline at Weeks 12, 16, 20, and 24
Change From Baseline at Week 24
-0.3 score on a scale
Standard Deviation 1.09
-1.5 score on a scale
Standard Deviation 1.54
-1.9 score on a scale
Standard Deviation 1.64

SECONDARY outcome

Timeframe: Weeks 12, 16, 20, and 24

Population: Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period.

SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied.

Outcome measures

Outcome measures
Measure
Placebo
n=140 Participants
Participants received CTP-543 matched placebo tablets, orally, BID for up to 24 weeks.
CTP-543 8 mg BID
n=351 Participants
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
CTP-543 12 mg BID
n=215 Participants
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Percentage of Participants Achieving a ≥2-point Change From Baseline in the SPRO Scale at Weeks 12, 16, 20, and 24
Week 12
20.7 percentage of participants
44.7 percentage of participants
53.1 percentage of participants
Percentage of Participants Achieving a ≥2-point Change From Baseline in the SPRO Scale at Weeks 12, 16, 20, and 24
Week 16
14.3 percentage of participants
48.1 percentage of participants
53.9 percentage of participants
Percentage of Participants Achieving a ≥2-point Change From Baseline in the SPRO Scale at Weeks 12, 16, 20, and 24
Week 20
13.7 percentage of participants
47.5 percentage of participants
57.5 percentage of participants
Percentage of Participants Achieving a ≥2-point Change From Baseline in the SPRO Scale at Weeks 12, 16, 20, and 24
Week 24
12.5 percentage of participants
49.1 percentage of participants
58.0 percentage of participants

SECONDARY outcome

Timeframe: Baseline, Weeks 12, 16, 20, and 24

Population: Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. Overall number of participants analyzed indicates the number of participants with data available for analysis of this outcome measure. Number of participants analyzed indicates the number of participants with data available for analysis at the specified timepoint.

The QPRO questionnaire provides additional details on key attributes of hair and helps provide context to the SPRO response. The individual items of QPRO are: Satisfied thickness hair coverage; Satisfied evenness hair coverage; How satisfied with your eyebrows; How satisfied with your eyelashes, scored on a scale ranging from 1 to 5 where 1=very satisfied, 2=satisfied, 3=neither satisfied nor dissatisfied, 4=dissatisfied, 5=very dissatisfied. Higher scores indicate the greater dissatisfaction on hair quality. A negative change from baseline indicate the greater satisfaction on hair quality.

Outcome measures

Outcome measures
Measure
Placebo
n=137 Participants
Participants received CTP-543 matched placebo tablets, orally, BID for up to 24 weeks.
CTP-543 8 mg BID
n=329 Participants
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
CTP-543 12 mg BID
n=209 Participants
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
Satisfied Evenness Hair Coverage: Change From Baseline at Week 24
-0.2 score on a scale
Standard Deviation 0.84
-1.2 score on a scale
Standard Deviation 1.41
-1.6 score on a scale
Standard Deviation 1.52
Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
How Satisfied With Your Eyebrows: Baseline
3.8 score on a scale
Standard Deviation 1.39
4.0 score on a scale
Standard Deviation 1.28
3.9 score on a scale
Standard Deviation 1.35
Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
How Satisfied With Your Eyebrows: Change From Baseline at Week 12
-0.2 score on a scale
Standard Deviation 0.88
-1.0 score on a scale
Standard Deviation 1.20
-1.1 score on a scale
Standard Deviation 1.34
Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
How Satisfied With Your Eyebrows: Change From Baseline at Week 16
-0.1 score on a scale
Standard Deviation 0.90
-1.1 score on a scale
Standard Deviation 1.24
-1.3 score on a scale
Standard Deviation 1.27
Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
How Satisfied With Your Eyebrows: Change From Baseline at Week 20
-0.2 score on a scale
Standard Deviation 0.88
-1.2 score on a scale
Standard Deviation 1.25
-1.4 score on a scale
Standard Deviation 1.32
Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
How Satisfied With Your Eyebrows: Change From Baseline at Week 24
-0.2 score on a scale
Standard Deviation 0.87
-1.2 score on a scale
Standard Deviation 1.26
-1.4 score on a scale
Standard Deviation 1.36
Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
How Satisfied With Your Eyelashes: Baseline
3.7 score on a scale
Standard Deviation 1.44
3.9 score on a scale
Standard Deviation 1.37
3.7 score on a scale
Standard Deviation 1.44
Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
How Satisfied With Your Eyelashes: Change From Baseline at Week 12
-0.3 score on a scale
Standard Deviation 0.79
-0.9 score on a scale
Standard Deviation 1.21
-0.9 score on a scale
Standard Deviation 1.24
Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
How Satisfied With Your Eyelashes: Change From Baseline at Week 16
-0.2 score on a scale
Standard Deviation 0.97
-1.0 score on a scale
Standard Deviation 1.24
-1.2 score on a scale
Standard Deviation 1.30
Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
How Satisfied With Your Eyelashes: Change From Baseline at Week 20
-0.3 score on a scale
Standard Deviation 0.99
-1.1 score on a scale
Standard Deviation 1.30
-1.1 score on a scale
Standard Deviation 1.33
Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
How Satisfied With Your Eyelashes: Change From Baseline at Week 24
-0.2 score on a scale
Standard Deviation 0.95
-1.1 score on a scale
Standard Deviation 1.37
-1.2 score on a scale
Standard Deviation 1.37
Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
Satisfied Thickness Hair Coverage: Baseline
4.5 score on a scale
Standard Deviation 0.79
4.6 score on a scale
Standard Deviation 0.79
4.5 score on a scale
Standard Deviation 0.76
Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
Satisfied Thickness Hair Coverage: Change From Baseline at Week 12
-0.4 score on a scale
Standard Deviation 0.98
-1.1 score on a scale
Standard Deviation 1.23
-1.3 score on a scale
Standard Deviation 1.17
Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
Satisfied Thickness Hair Coverage: Change From Baseline at Week 16
-0.3 score on a scale
Standard Deviation 1.03
-1.2 score on a scale
Standard Deviation 1.28
-1.5 score on a scale
Standard Deviation 1.33
Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
Satisfied Thickness Hair Coverage: Change From Baseline at Week 20
-0.3 score on a scale
Standard Deviation 0.98
-1.3 score on a scale
Standard Deviation 1.35
-1.6 score on a scale
Standard Deviation 1.36
Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
Satisfied Thickness Hair Coverage: Change From Baseline at Week 24
-0.2 score on a scale
Standard Deviation 1.00
-1.4 score on a scale
Standard Deviation 1.43
-1.7 score on a scale
Standard Deviation 1.45
Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
Satisfied Evenness Hair Coverage: Baseline
4.6 score on a scale
Standard Deviation 0.67
4.6 score on a scale
Standard Deviation 0.76
4.6 score on a scale
Standard Deviation 0.68
Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
Satisfied Evenness Hair Coverage: Change From Baseline at Week 12
-0.4 score on a scale
Standard Deviation 0.83
-1.0 score on a scale
Standard Deviation 1.19
-1.3 score on a scale
Standard Deviation 1.16
Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
Satisfied Evenness Hair Coverage: Change From Baseline at Week 16
-0.3 score on a scale
Standard Deviation 0.84
-1.1 score on a scale
Standard Deviation 1.31
-1.4 score on a scale
Standard Deviation 1.34
Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
Satisfied Evenness Hair Coverage: Change From Baseline at Week 20
-0.3 score on a scale
Standard Deviation 0.90
-1.2 score on a scale
Standard Deviation 1.36
-1.5 score on a scale
Standard Deviation 1.40

SECONDARY outcome

Timeframe: Baseline and Week 24

Population: Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. Overall number of participants analyzed indicates the number of participants with data available for analysis of this outcome measure. Number of participants analyzed indicates the number of participants with data available for analysis at the specified timepoint.

HADS is a questionnaire designed to assess anxiety and depression symptoms which is completed by participants. The questionnaire is comprised of two separate scales with a total of 14 items: A 7-item scale related to anxiety and 7-item scale related to depression. Each item within both scales is scored using a 4-point scale, ranging from 0 to 3 and the total scores in each scale can range from 0 to 21. Separate scores were created for anxiety and depression. A score between 0-7 is considered normal, 8-10 is mild, 11-14 is moderate, and \>14 is severe anxiety or depression. Higher scores indicate greater severity. A negative change from baseline indicates less severity.

Outcome measures

Outcome measures
Measure
Placebo
n=128 Participants
Participants received CTP-543 matched placebo tablets, orally, BID for up to 24 weeks.
CTP-543 8 mg BID
n=318 Participants
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
CTP-543 12 mg BID
n=200 Participants
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Change in the Anxiety and Depression Scale Scores of the Hospital Anxiety and Depression Scale (HADS) From Baseline at Week 24
Anxiety: Baseline
5.5 score on a scale
Standard Deviation 3.92
6.2 score on a scale
Standard Deviation 4.06
6.0 score on a scale
Standard Deviation 3.92
Change in the Anxiety and Depression Scale Scores of the Hospital Anxiety and Depression Scale (HADS) From Baseline at Week 24
Anxiety: Change From Baseline at Week 24
-0.4 score on a scale
Standard Deviation 2.98
-1.0 score on a scale
Standard Deviation 3.26
-1.1 score on a scale
Standard Deviation 3.24
Change in the Anxiety and Depression Scale Scores of the Hospital Anxiety and Depression Scale (HADS) From Baseline at Week 24
Depression: Baseline
3.3 score on a scale
Standard Deviation 3.06
3.7 score on a scale
Standard Deviation 3.31
3.6 score on a scale
Standard Deviation 3.39
Change in the Anxiety and Depression Scale Scores of the Hospital Anxiety and Depression Scale (HADS) From Baseline at Week 24
Depression: Change From Baseline at Week 24
-0.7 score on a scale
Standard Deviation 2.67
-0.9 score on a scale
Standard Deviation 2.93
-1.1 score on a scale
Standard Deviation 2.88

SECONDARY outcome

Timeframe: Week 24

Population: Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period.

SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).

Outcome measures

Outcome measures
Measure
Placebo
n=140 Participants
Participants received CTP-543 matched placebo tablets, orally, BID for up to 24 weeks.
CTP-543 8 mg BID
n=351 Participants
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
CTP-543 12 mg BID
n=215 Participants
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Percentage of Participants Achieving an Absolute SALT Score of ≤10 at Week 24
0 percentage of participants
20.8 percentage of participants
34.5 percentage of participants

Adverse Events

Placebo

Serious events: 4 serious events
Other events: 31 other events
Deaths: 0 deaths

CTP-543 8 mg BID

Serious events: 4 serious events
Other events: 117 other events
Deaths: 0 deaths

CTP-543 12 mg BID

Serious events: 1 serious events
Other events: 75 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Placebo
n=140 participants at risk
Participants received CTP-543 matched placebo tablets, orally, BID for up to 24 weeks.
CTP-543 8 mg BID
n=350 participants at risk
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
CTP-543 12 mg BID
n=215 participants at risk
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Infections and infestations
Appendicitis
0.71%
1/140 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
0.29%
1/350 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
0.47%
1/215 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
Infections and infestations
COVID-19
0.00%
0/140 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
0.29%
1/350 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
0.00%
0/215 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
Infections and infestations
Meningitis
0.00%
0/140 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
0.29%
1/350 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
0.00%
0/215 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
General disorders
Chest pain
0.00%
0/140 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
0.29%
1/350 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
0.00%
0/215 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
General disorders
Pyrexia
0.00%
0/140 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
0.29%
1/350 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
0.00%
0/215 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
Gastrointestinal disorders
Ileus
0.00%
0/140 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
0.00%
0/350 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
0.47%
1/215 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
Nervous system disorders
Epilepsy
0.71%
1/140 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
0.00%
0/350 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
0.00%
0/215 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
Pregnancy, puerperium and perinatal conditions
Abortion spontaneous
0.71%
1/140 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
0.00%
0/350 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
0.00%
0/215 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
Psychiatric disorders
Adjustment disorder
0.71%
1/140 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
0.00%
0/350 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
0.00%
0/215 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
Respiratory, thoracic and mediastinal disorders
Dyspnoea
0.00%
0/140 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
0.29%
1/350 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
0.00%
0/215 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.

Other adverse events

Other adverse events
Measure
Placebo
n=140 participants at risk
Participants received CTP-543 matched placebo tablets, orally, BID for up to 24 weeks.
CTP-543 8 mg BID
n=350 participants at risk
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
CTP-543 12 mg BID
n=215 participants at risk
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Infections and infestations
COVID-19
5.7%
8/140 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
5.4%
19/350 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
7.0%
15/215 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
Infections and infestations
Nasopharyngitis
3.6%
5/140 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
5.1%
18/350 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
3.7%
8/215 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
Infections and infestations
Upper respiratory tract infection
6.4%
9/140 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
2.6%
9/350 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
3.7%
8/215 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
Investigations
Blood creatine phosphokinase (increased)
1.4%
2/140 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
6.0%
21/350 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
5.1%
11/215 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
Nervous system disorders
Headache
5.7%
8/140 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
11.7%
41/350 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
11.2%
24/215 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
Skin and subcutaneous tissue disorders
Acne
5.0%
7/140 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
8.9%
31/350 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.
12.1%
26/215 • All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28)
All-cause mortality: All randomized participants included all participants who were randomized in the study. Adverse events: Safety population included all participants who received study drug during the treatment period.

Additional Information

Colleen E. Hamilton

Concert Pharmaceuticals, Inc.

Phone: 781-860-0045

Results disclosure agreements

  • Principal investigator is a sponsor employee If an Investigator wants to publish study data or results, the publication or presentation must be provided to Concert for review at least 60 days in advance. If Concert needs to file a patent application prior to publication, the publication can be delayed up to 90 days from Sponsor providing notice to the investigator of such need.
  • Publication restrictions are in place

Restriction type: OTHER